Skip to main content

Table 3 Predictors of clinical remission and prednisone discontinuation

From: The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients

 

Odds Ratio (95% CI)

p #

Responder at 2 months:

 Printo-50

(vs. not responder/Printo-20)

5.41 (1.37–21.32)

0.0076

 Printo-70

(vs. not responder/Printo-20)

6.90 (1.91–24.99)

 

 Printo-90

(vs. not responder/Printo-20)

4.46 (1.08–18.38)

 

 Onset age > 8.53 years

(vs. ≤ 8.53 years)

4.64 (1.69–12.71)

0.0017

 Therapygroup: PDN + MTX

(vs. PDN/PDN + CSA)

3.63 (1.30–10.09)

0.0116

 AUC of the model

0.80

 
  1. PDN prednisone, MTX methotrexate, CSA Cyclosporine. OR Odds Ratio, 95% CI 95% Confidence Interval; p#: Likelihood Ratio test